Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Japan’s Kyorin Pharmaceutical has entered into a global license agreement with Swiss pharma giant Novartis relating to ...

Kyorin Pharmaceutical Co. Ltd. has out-licensed its preclinical candidate, KRP-M223, and its back-up compounds to Novartis Pharma AG in a deal worth up to $777.5 million. Under the terms, Novartis ...

The U.K has released a huge repository of children’s genomic data after sequencing blood samples from three large cohorts recruited at birth and followed across three decades. The power of the data is ...

M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.

IN8bio has unveiled a new T cell engager (TCE) platform, marking its first major push into autoimmune disease. The biotech, which previously focused on oncology, introduced INB-619, a CD19-targeted ...

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

Novartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that hasn’t stopped it making a strong start in the US market. Zolgensma (onasemnogene ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BridgeBio Oncology Therapeutics, a cancer drug startup spun out of biotechnology company BridgeBio Pharma, will go public by merging with a blank-check entity. In a deal announced Friday, BridgeBio ...

Merck & Co.’s cancer immunotherapy Keytruda is one of the pharmaceutical industry’s biggest successes. The drug's arrival in 2014 introduced a new way of treating cancer and, over time, it became ...